Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW5004 tablets combined with pembrolizumab in advanced solid tumors after standard treatment failure (Ib/II study)
CTR20232577Phase 2Active
- Sponsor
- Sinovent
- Start
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of igermetostat, pembrolizumab in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), transitional cell carcinoma (TCC), prostate adenocarcinoma, sponsored by Sinovent. Started Sep 2023; status: active.
02
Drugs
igermetostatpembrolizumab
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)transitional cell carcinoma (TCC)prostate adenocarcinoma
Beyond the preview
Go deeper on CTR20232577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232577.